definiens: means with respect to each Co - DevelopedDevelopment Candidate, the lesser of ( a ) the ARCHEMIX Co - Development Participation Capacity with respect to such Co - Developed Development Candidate and ; ( b ) with respect to the ARCHEMIX [ * * * ] % Co - Development Sharing Percentage(i ) for any Development activities conducted with respect to a Co - Developed Development Candidate at any time during theperiod commencing on the date of exercise by ARCHEMIX of the Co - Development and Co - Promotion Option with respect tosuch Co - Developed Development Candidate and continuing until the Initiation of Phase I Clinical Trials with respect to suchCo - Developed Development Candidate, a number of ARCHEMIX FTEs equal to [ * * * ] percent ( [ * * * ] % ) of the EstimatedAggregate FTEs ; ( ii ) for any Development activities conducted with respect to a Co - Developed Development Candidate atany time during the period commencing on the Initiation of Phase I Clinical Trials with respect to such Co - DevelopedDevelopment Candidate and continuing until the Initiation of Phase II Clinical Trials with respect to such Co - DevelopedDevelopment Candidate, a number of ARCHEMIX FTEs equal to [ * * * ] percent ( [ * * * ] % ) of the Estimated Aggregate FTEs;and ( iii ) for any Development activities conducted with respect to a Co - Developed Development Candidate during the periodcommencing on the Initiation of Phase II Clinical Trials with respect to such Co - Developed Development Candidate andcontinuing until the completion of Phase III Clinical Trials with respect to such Co - Developed Development Candidate ( the ), a number of ARCHEMIX FTEs equal to [ * * * ] percent ( [ * * * ] % ) of the EstimatedAggregate FTEs, or ( c)Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to to theCompany ’s application requesting confidential treatment under Rule 406 of the Securities Act